These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35292802)

  • 1. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
    Berlanga P; Pierron G; Lacroix L; Chicard M; Adam de Beaumais T; Marchais A; Harttrampf AC; Iddir Y; Larive A; Soriano Fernandez A; Hezam I; Chevassus C; Bernard V; Cotteret S; Scoazec JY; Gauthier A; Abbou S; Corradini N; André N; Aerts I; Thebaud E; Casanova M; Owens C; Hladun-Alvaro R; Michiels S; Delattre O; Vassal G; Schleiermacher G; Geoerger B
    Cancer Discov; 2022 May; 12(5):1266-1281. PubMed ID: 35292802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
    Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P
    Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART.
    Geoerger B; Bautista F; André N; Berlanga P; Gatz SA; Marshall LV; Rubino J; Archambaud B; Marchais A; Rubio-San-Simón A; Ducassou S; Zwaan CM; Casanova M; Nysom K; Pellegrino S; Hoog-Labouret N; Buzyn A; Blanc P; Paoletti X; Vassal G
    Eur J Cancer; 2024 Sep; 208():114201. PubMed ID: 39018630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
    Trédan O; Wang Q; Pissaloux D; Cassier P; de la Fouchardière A; Fayette J; Desseigne F; Ray-Coquard I; de la Fouchardière C; Frappaz D; Heudel PE; Bonneville-Levard A; Fléchon A; Sarabi M; Guibert P; Bachelot T; Pérol M; You B; Bonnin N; Collard O; Leyronnas C; Attignon V; Baudet C; Sohier E; Villemin JP; Viari A; Boyault S; Lantuejoul S; Paindavoine S; Treillleux I; Rodriguez C; Agrapart V; Corset V; Garin G; Chabaud S; Pérol D; Blay JY;
    Ann Oncol; 2019 May; 30(5):757-765. PubMed ID: 30865223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
    Marques Da Costa ME; Zaidi S; Scoazec JY; Droit R; Lim WC; Marchais A; Salmon J; Cherkaoui S; Morscher RJ; Laurent A; Malinge S; Mercher T; Tabone-Eglinger S; Goddard I; Pflumio F; Calvo J; Redini F; Entz-Werlé N; Soriano A; Villanueva A; Cairo S; Chastagner P; Moro M; Owens C; Casanova M; Hladun-Alvaro R; Berlanga P; Daudigeos-Dubus E; Dessen P; Zitvogel L; Lacroix L; Pierron G; Delattre O; Schleiermacher G; Surdez D; Geoerger B
    Commun Biol; 2023 Sep; 6(1):949. PubMed ID: 37723198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
    Westbrook TC; Hagemann IS; Ley J; Chen K; Palka K; Liu J; Chen L; Oppelt P; Adkins D
    Med Oncol; 2019 Dec; 37(2):12. PubMed ID: 31865465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
    Langenberg KPS; Meister MT; Bakhuizen JJ; Boer JM; van Eijkelenburg NKA; Hulleman E; Ilan U; Looze EJ; Dierselhuis MP; van der Lugt J; Breunis W; Schild LG; Ober K; van Hooff SR; Scheijde-Vermeulen MA; Hiemcke-Jiwa LS; Flucke UE; Kranendonk MEG; Wesseling P; Sonneveld E; Punt S; Boltjes A; van Dijk F; Verwiel ETP; Volckmann R; Hehir-Kwa JY; Kester LA; Koudijs MMJ; Waanders E; Holstege FCP; Vormoor HJ; Hoving EW; van Noesel MM; Pieters R; Kool M; Stumpf M; Blattner-Johnson M; Balasubramanian GP; Van Tilburg CM; Jones BC; Jones DTW; Witt O; Pfister SM; Jongmans MCJ; Kuiper RP; de Krijger RR; Wijnen MHW; den Boer ML; Zwaan CM; Kemmeren P; Koster J; Tops BBJ; Goemans BF; Molenaar JJ
    Eur J Cancer; 2022 Nov; 175():311-325. PubMed ID: 36182817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
    Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
    Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.
    Ecker J; Selt F; Sturm D; Sill M; Korshunov A; Hirsch S; Capper D; Dikow N; Sutter C; Müller C; Sigaud R; Eggert A; Simon T; Niehues T; von Deimling A; Pajtler KW; van Tilburg CM; Jones DTW; Sahm F; Pfister SM; Witt O; Milde T
    Eur J Cancer; 2023 Feb; 180():71-84. PubMed ID: 36542877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 19. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
    Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.